Stonegate Capital Partners provides an update on Alpha Cognition Inc., highlighting the company's achievements in 2024. These include raising $52.8 million, uplisting to NASDAQ, securing a new U.S. patent, and completing a Department of Defense-funded study. With FDA approval for their Alzheimer's treatment, ZUNVEYL, the company is focusing on the LTC market. Positive early results in their go-to-market strategy and a licensing deal with China Medical Systems Holdings indicate strong potential for expansion. ACOG's strong management team and financial foundation inspire confidence in their commercialization strategy.